Over the last five decades, progress in neural recording techniques has allowed the number of simultaneously recorded neurons to double approximately every 7 years, mimicking Moore’s law. Following Stevenson and Kording (2011), this site aims to keep track of these advances in electrophysiology. If you notice a missing data point email me with a reference and the number of neurons recorded.
Exposure to endocrine-disrupting chemicals in early life, including during gestation and infancy, results in a higher preference for sugary and fatty foods later in life, according to an animal study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
Endocrine-disrupting chemicals are substances in the environment (air, soil or water supply), food sources, personal care products and manufactured products that interfere with the normal function of the body’s endocrine system. To determine if early-life exposure to these chemicals affects eating behaviors and preferences, researchers from the University of Texas at Austin conducted a study of 15 male and 15 female rats exposed to a common mixture of these chemicals during gestation or infancy.
“Our research indicates that endocrine-disrupting chemicals can physically alter the brain’s pathways that control reward preference and eating behavior. These results may partially explain increasing rates of obesity around the world,” said Emily N. Hilz, Ph.D., a postdoctoral research fellow at the University of Texas at Austin in Austin, Texas.
Researchers at the University of Southern California have made a significant breakthrough in understanding how the human brain forms, stores and recalls visual memories. A new study, published in Advanced Science, harnesses human patient brain recordings and a powerful machine learning model to shed new light on the brain’s internal code that sorts memories of objects into categories—think of it as the brain’s filing cabinet of imagery.
The results demonstrated that the research team could essentially read subjects’ minds, by pinpointing the category of visual image being recalled, purely from the precise timing of the subject’s neural activity.
The work solves a fundamental neuroscience debate and offers exciting potential for future brain-computer interfaces, including memory prostheses to restore lost memory in patients with neurological disorders like dementia.
University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to clear pathological tau protein from the brains of patients suffering from Alzheimer’s dementia.
The Phase 1a/1b trial, supported in part by a $1 million grant from the Alzheimer’s Association’s Part the Cloud initiative, will test the novel vaccine, which was developed by UNM School of Medicine scientists, said Kiran Bhaskar, PhD, professor in the Departments of Molecular Genetics & Microbiology and Neurology.
“The primary endpoint of this study is safety and tolerability,” he said. “Can these subjects take these vaccinations without any anticipated side effects or adverse events? The second endpoint is the immunogenicity – can they make antibodies to tau?”
Starting today, people with Parkinson’s disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.
The therapy, known as adaptive deep brain stimulation, or aDBS, uses an implanted device that continuously monitors the brain for signs that Parkinson’s symptoms are developing. When it detects specific patterns of brain activity, it delivers precisely calibrated electric pulses to keep symptoms at bay.
The FDA approval covers two treatment algorithms that run on a device made by Medtronic, a medical device company. Both work by monitoring the same part of the brain, called the subthalamic nucleus. But they respond in different ways.
The FDA has approved an adaptive deep brain stimulation (aDBS) treatment for people with with Parkinson’s disease, making this groundbreaking technology available to people nationwide.
This week: The US Food and Drug Administration (FDA; MD, USA) has granted a special exemption for an iPSC-derived cell therapy targeting Parkinson’s disease, along with Breakthrough Therapy designations for a CAR-T therapy for a pediatric brain tumor and a gene therapy for Huntington’s disease.
The FDA has granted XellSmart Biopharmaceutical (Suzhou, China) a special exemption to support a clinical trial of XS-411 Injection, the company’s allogeneic, off-the-shelf iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson’s disease. This follows an Investigational New Drug submission in January 2025. In parallel, China’s National Medical Products Administration has approved XS-411 to enter Phase I clinical trials.
Additionally, the FDA has cleared XellSmart’s XS228, an allogeneic, off-the-shelf, clinical-grade iPSC-derived cell therapy for amyotrophic lateral sclerosis (ALS), to begin Phase I trials, marking it as the first-in-class regenerative neural cell therapy for the disease.
The FDA has granted a special exemption for a cell therapy and Breakthrough Therapy designations for a CAR-T therapy and a gene therapy.
